Last reviewed · How we verify
Intravenous albumin
Intravenous albumin restores intravascular oncotic pressure and improves plasma volume expansion in hypovolemic or critically ill patients.
Intravenous albumin restores intravascular oncotic pressure and improves plasma volume expansion in hypovolemic or critically ill patients. Used for Hypovolemic shock or severe hypoalbuminemia in critically ill patients, Plasma volume expansion in acute blood loss or severe burns, Hepatic cirrhosis with ascites and renal dysfunction.
At a glance
| Generic name | Intravenous albumin |
|---|---|
| Sponsor | Hamilton Health Sciences Corporation |
| Drug class | Colloid volume expander / Plasma protein fraction |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Intensive Care Medicine |
| Phase | Phase 3 |
Mechanism of action
Albumin is a naturally occurring plasma protein that acts as a colloid, drawing and retaining fluid in the intravascular space to maintain adequate circulating blood volume and tissue perfusion. It also serves as a carrier protein for various endogenous and exogenous substances, and has antioxidant and anti-inflammatory properties that may reduce organ dysfunction in critical illness.
Approved indications
- Hypovolemic shock or severe hypoalbuminemia in critically ill patients
- Plasma volume expansion in acute blood loss or severe burns
- Hepatic cirrhosis with ascites and renal dysfunction
Common side effects
- Hypervolemia / fluid overload
- Pulmonary edema
- Allergic reaction / fever
- Hypertension
Key clinical trials
- Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] (PHASE3)
- Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma (PHASE2)
- A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors (PHASE1, PHASE2)
- A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) (PHASE3)
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) (PHASE3)
- ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer (PHASE3)
- A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) (PHASE2)
- Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous albumin CI brief — competitive landscape report
- Intravenous albumin updates RSS · CI watch RSS
- Hamilton Health Sciences Corporation portfolio CI